Selene Peng

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.